ANAB:NGS-AnaptysBio Inc. (USD)

COMMON STOCK | Biotechnology | Nasdaq Global Select

Last Closing

USD 40.33

Change

+2.03 (+5.30)%

Market Cap

USD 0.57B

Volume

0.58M

Analyst Target

USD 18.14
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

AnaptysBio Inc is a biotechnology company. The Company is engaged in developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. Its product include ANB020 and ANB019.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-6.33 (-0.55%)

USD 127.14B
VRTX Vertex Pharmaceuticals Inc

-8.17 (-1.67%)

USD 125.27B
ALNY Alnylam Pharmaceuticals Inc

+4.09 (+1.51%)

USD 34.71B
ARGX argenx NV ADR

-15.72 (-2.92%)

USD 32.33B
MRNA Moderna Inc

+2.82 (+4.08%)

USD 26.25B
SMMT Summit Therapeutics PLC

-3.26 (-11.06%)

USD 23.47B
BGNE BeiGene Ltd

+1.06 (+0.54%)

USD 21.94B
RPRX Royalty Pharma Plc

-0.02 (-0.07%)

USD 16.45B
BMRN Biomarin Pharmaceutical Inc

+0.69 (+0.99%)

USD 16.16B
UTHR United Therapeutics Corporatio..

+0.04 (+0.01%)

USD 15.09B

ETFs Containing ANAB

BBC Virtus LifeSci Biotech Cl.. 1.30 % 0.79 %

-0.21 (-0.73%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 88.28% 90% A- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 88.28% 89% A- 94% A
Trailing 12 Months  
Capital Gain 106.82% 88% B+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 106.82% 88% B+ 95% A
Trailing 5 Years  
Capital Gain -8.59% 68% D+ 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.59% 68% D+ 40% F
Average Annual (5 Year Horizon)  
Capital Gain 11.89% 68% D+ 69% C-
Dividend Return 11.89% 68% D+ 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 39.53% 71% C- 46% F
Risk Adjusted Return 30.08% 84% B 63% D
Market Capitalization 0.57B 82% B 73% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector